Treatment of type II diabetes; Early detection of secondary oral treatment failure important;Behandling av typ 2-diabetes: Viktigt med tidigare upptäckt av sekundärsvikt vid tablettbehandling

Lakartidningen

Volumn 96, Issue 3, 1999, Pages 176-181

  Clauson, Per ^a,b   Efendic, Suad ^c  

^a NOVO NORDISK A S   (Denmark)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

DRUG COMBINATION; HUMAN; INSULIN RESISTANCE; LIFESTYLE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; REVIEW; SECRETION; TABLET; TREATMENT FAILURE;

ADMINISTRATION, ORAL; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIFE STYLE; TABLETS; TREATMENT FAILURE;

EID: 0033585269     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Efendic S, Luft R, Wajngot A. Aspects of the pathogenesis of type 2 diabetes. Endocr Rev 1984; 5: 395-410.
2. Cerasi E. Insulin deficiency and insulin resistance in the pathogenesis of NIDDM: is a divorce possible? Diabetologia 1995; 38: 992-7.
3. Andersson DKG, Svärdsudd K, Tibblin G. Prevalence and incidence of diabetes in a Swedish community 1972, 1987. Diabet Med 1991; 8: 428-34.
4. Midthjell K, Björndal A, Holmen J, Krüger Ø, Bjartveit K. Prevalence of known and previously unknown diabetes mellitus and impaired glucose tolerance in an adult Norwegian population. Indications of an increasing diabetes prevalence. The Nord-Tröndelag diabetes study. Scand J Prim Health Care 1995; 13: 229-35.
5. Lithman T, Noreen D, Norlund A. Prevalens, vård och vårdkostnader för vårdtunga grupper. SOU 1996:163. Delbetänkande av HSU 2000: Behov och resurser i vården-en analys.
6. Gerich JE. Pathogenesis and treatment of type 2 (non insulin-dependent) diabetes mellitus (NIDDM). Horm Metab Res 1996; 28: 404-12.
7. Hermann LS. Metformin as monotherapy and combined with glibenclamide in patients with non-insulin dependent diabetes mellitus [dissertation] Lund: Lund University, 1994.
8. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1(7-36)amide in normal subjects and patients with diabetes mellitus. N Engl JMed 1992; 326: 1316-22.
9. Juntti-Berggren L, Pigon J, Karpe F, Hamsten A, Gutniak M, Vignati L et al. The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients. Diabetes Care 1996; 19: 1200-6.
10. Rönnemaa T, Laakso M, Pyörälä K, Kallio V, Puukka P. High fasting plasma insulin is an indicator of coronary heart disease in non-insulin-dependent diabetic patients and nondiabetic subjects. Arterioscler Thromb 1991; 11: 80-90.
11. Barnett AH, Bowen Jones D, Burden AC, Janes JM, Sinclair A, Samall M et al. Multicentre study to assess quality of life and glycaemic control of type 2 diabetic patients treated with insulin compared with oral hypoglycaemic agents Practical Diabetes International 1996; 13: 179-83.
12. Riddle M. New tactics for type 2 diabetes: regimens based on intermediate-acting insulin taken at bedtime. Lancet 1985; 1: 192-5.
13. Peters AL, Davidson MB. Insulin plus a sulfonylurea agent for treating type 2 diabetes. Ann Intern Med 1991; 115: 45-53.
14. Pugh JA, Wagner ML, Sawyer J, Ramirez G, Tuley M, Friedberg SJ. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis. Diabet Care 1992; 15: 953-9.
15. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type 2 diabetes. A meta-analysis of the randomized placebo-controlled trials. Arch Intern Med 1996; 156: 259-4.
16. Garvey W, Olefsky J, Griffin J, Hamman R, Kolterman O. The effect of insulin treatment on insulin secretion and insulin action in type 2 diabetes mellitus. Diabetes 1985; 34: 222-4.
17. Clauson P, Karlander S, Steen L, Efendic S. Day-time glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: A one year follow up. Diabet Med 1996; 13: 471-7
18. Yki-Järvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L et al. Comparison of insulin regimes in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327: 1426-33.
19. Yki-Järvinen H, Nikkilä K, Ryysy L, Tulokas T, Vanamo R, Heikkilä M. New thoughts of insulin therapy in NIDDM. Abstracts for the State-of-the-Art Lectures and Symposia. 16th International Diabetes Federation Congress. Helsinki, 1997.